Système de signalisation des MAP kinases : Questions médicales fréquentes
Nom anglais: MAP Kinase Signaling System
Descriptor UI:D020935
Tree Number:G04.835.560
Termes MeSH sélectionnés :
Genetic Code
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Système de signalisation des MAP kinases : Questions médicales les plus fréquentes",
"headline": "Système de signalisation des MAP kinases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Système de signalisation des MAP kinases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-26",
"dateModified": "2025-04-20",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Système de signalisation des MAP kinases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Transduction du signal",
"url": "https://questionsmedicales.fr/mesh/D015398",
"about": {
"@type": "MedicalCondition",
"name": "Transduction du signal",
"code": {
"@type": "MedicalCode",
"code": "D015398",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G04.835"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Système de signalisation des MAP kinases",
"alternateName": "MAP Kinase Signaling System",
"code": {
"@type": "MedicalCode",
"code": "D020935",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "David S Waddell",
"url": "https://questionsmedicales.fr/author/David%20S%20Waddell",
"affiliation": {
"@type": "Organization",
"name": "University of North Florida, Department of Biology, 1 UNF Drive, Jacksonville, FL 32224, USA. Electronic address: d.s.waddell@unf.edu."
}
},
{
"@type": "Person",
"name": "Yuelin Zhang",
"url": "https://questionsmedicales.fr/author/Yuelin%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Botany, University of British Columbia, Vancouver, BC, Canada."
}
},
{
"@type": "Person",
"name": "Emmanuel Prikas",
"url": "https://questionsmedicales.fr/author/Emmanuel%20Prikas",
"affiliation": {
"@type": "Organization",
"name": "Dementia Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia."
}
},
{
"@type": "Person",
"name": "Arne Ittner",
"url": "https://questionsmedicales.fr/author/Arne%20Ittner",
"affiliation": {
"@type": "Organization",
"name": "Dementia Research Centre, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW, Australia."
}
},
{
"@type": "Person",
"name": "T S Keshava Prasad",
"url": "https://questionsmedicales.fr/author/T%20S%20Keshava%20Prasad",
"affiliation": {
"@type": "Organization",
"name": "Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, 575018, India. keshav@yenepoya.edu.in."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "STAT3-dependent long non-coding RNA Lncenc1 contributes to mouse ES cells pluripotency via stabilizing K mRNA.",
"datePublished": "2023-10-04",
"url": "https://questionsmedicales.fr/article/37801430",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1093/bfgp/elad045"
}
},
{
"@type": "ScholarlyArticle",
"name": "Identification and validation of a novel anoikis-related long non-coding RNA signature for pancreatic adenocarcinoma to predict the prognosis and immune response.",
"datePublished": "2023-08-24",
"url": "https://questionsmedicales.fr/article/37620430",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00432-023-05285-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "Long non-coding RNA PANDAR promoted radiation and cisplatin-induced DNA damage repair through ATR/CHK1 in NSCLC.",
"datePublished": "2023-07-17",
"url": "https://questionsmedicales.fr/article/37460393",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jgm.3565"
}
},
{
"@type": "ScholarlyArticle",
"name": "1-Bit Transmission-Type Digital Programmable Coding Metasurface with Multi-Functional Beam-Shaping Capability for Ka-Band Applications.",
"datePublished": "2023-06-14",
"url": "https://questionsmedicales.fr/article/37374835",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/mi14061250"
}
},
{
"@type": "ScholarlyArticle",
"name": "Improving the timeliness and completeness of childhood vaccination through color-coded bracelets: a pilot study among Fulani tribe populations in Nigeria.",
"datePublished": "2023-05-03",
"url": "https://questionsmedicales.fr/article/37441119",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4081/jphia.2023.2079"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes physiologiques cellulaires",
"item": "https://questionsmedicales.fr/mesh/D002468"
},
{
"@type": "ListItem",
"position": 3,
"name": "Transduction du signal",
"item": "https://questionsmedicales.fr/mesh/D015398"
},
{
"@type": "ListItem",
"position": 4,
"name": "Système de signalisation des MAP kinases",
"item": "https://questionsmedicales.fr/mesh/D020935"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Système de signalisation des MAP kinases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Système de signalisation des MAP kinases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Système de signalisation des MAP kinases",
"description": "Comment diagnostiquer une dysrégulation des MAP kinases ?\nQuels tests sont utilisés pour évaluer les MAP kinases ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels marqueurs biologiques sont associés aux MAP kinases ?\nPeut-on utiliser l'imagerie pour diagnostiquer des troubles liés aux MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Genetic+Code&page=1000#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Système de signalisation des MAP kinases",
"description": "Quels symptômes indiquent une activation anormale des MAP kinases ?\nLes troubles neurologiques sont-ils liés aux MAP kinases ?\nComment les MAP kinases affectent-elles le cancer ?\nLes maladies auto-immunes sont-elles liées aux MAP kinases ?\nQuels signes cliniques sont associés à une inflammation chronique ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Genetic+Code&page=1000#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Système de signalisation des MAP kinases",
"description": "Peut-on prévenir les troubles liés aux MAP kinases ?\nLes examens réguliers aident-ils à prévenir les maladies liées aux MAP kinases ?\nL'évitement de certains médicaments peut-il prévenir des dysfonctionnements des MAP kinases ?\nComment le stress influence-t-il les MAP kinases ?\nLes vaccinations peuvent-elles influencer la signalisation des MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Genetic+Code&page=1000#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Système de signalisation des MAP kinases",
"description": "Quels traitements ciblent les MAP kinases dans le cancer ?\nLes thérapies géniques peuvent-elles corriger les anomalies des MAP kinases ?\nComment les anti-inflammatoires affectent-ils les MAP kinases ?\nLes traitements ciblés sont-ils efficaces contre les maladies liées aux MAP kinases ?\nQuels sont les effets secondaires des inhibiteurs de MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Genetic+Code&page=1000#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Système de signalisation des MAP kinases",
"description": "Quelles complications peuvent survenir avec une activation excessive des MAP kinases ?\nLes troubles cardiovasculaires sont-ils liés aux MAP kinases ?\nComment les MAP kinases sont-elles impliquées dans le diabète ?\nLes maladies neurodégénératives sont-elles liées aux MAP kinases ?\nQuelles sont les conséquences d'une inhibition des MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Genetic+Code&page=1000#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Système de signalisation des MAP kinases",
"description": "Quels facteurs de risque sont associés aux troubles des MAP kinases ?\nLe mode de vie influence-t-il les risques liés aux MAP kinases ?\nL'âge est-il un facteur de risque pour les troubles des MAP kinases ?\nLes infections peuvent-elles influencer les MAP kinases ?\nLe tabagisme est-il un facteur de risque pour les troubles des MAP kinases ?",
"url": "https://questionsmedicales.fr/mesh/D020935?mesh_terms=Genetic+Code&page=1000#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysrégulation des MAP kinases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses de protéines peuvent aider à identifier des anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les MAP kinases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'immunoblotting et la cytométrie en flux pour mesurer l'activité."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des biopsies peuvent être nécessaires pour évaluer l'expression des MAP kinases."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux MAP kinases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs comme ERK, JNK et p38 sont souvent analysés dans les études."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'imagerie pour diagnostiquer des troubles liés aux MAP kinases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'imagerie peut aider à visualiser des tumeurs, mais ne cible pas directement les MAP kinases."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une activation anormale des MAP kinases ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes peuvent inclure inflammation, douleur et croissance cellulaire anormale."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés aux MAP kinases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements des MAP kinases peuvent contribuer à des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Comment les MAP kinases affectent-elles le cancer ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une activation excessive des MAP kinases peut favoriser la prolifération tumorale."
}
},
{
"@type": "Question",
"name": "Les maladies auto-immunes sont-elles liées aux MAP kinases ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans la signalisation des MAP kinases peuvent exacerber les maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à une inflammation chronique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rougeur, chaleur, gonflement et douleur sont des signes d'inflammation chronique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés aux MAP kinases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un mode de vie actif peuvent réduire les risques associés."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à prévenir les maladies liées aux MAP kinases ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des anomalies."
}
},
{
"@type": "Question",
"name": "L'évitement de certains médicaments peut-il prévenir des dysfonctionnements des MAP kinases ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, éviter certains médicaments peut réduire le risque de dysrégulation des MAP kinases."
}
},
{
"@type": "Question",
"name": "Comment le stress influence-t-il les MAP kinases ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut activer les MAP kinases, contribuant à des maladies."
}
},
{
"@type": "Question",
"name": "Les vaccinations peuvent-elles influencer la signalisation des MAP kinases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines vaccinations peuvent moduler la réponse immunitaire via les MAP kinases."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les MAP kinases dans le cancer ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs spécifiques des MAP kinases, comme les inhibiteurs de MEK, sont utilisés."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques peuvent-elles corriger les anomalies des MAP kinases ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique peut potentiellement corriger des mutations affectant les MAP kinases."
}
},
{
"@type": "Question",
"name": "Comment les anti-inflammatoires affectent-ils les MAP kinases ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les anti-inflammatoires peuvent inhiber l'activation des MAP kinases, réduisant l'inflammation."
}
},
{
"@type": "Question",
"name": "Les traitements ciblés sont-ils efficaces contre les maladies liées aux MAP kinases ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements ciblés montrent des résultats prometteurs dans certaines pathologies."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des inhibiteurs de MAP kinases ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure fatigue, éruptions cutanées et troubles gastro-intestinaux."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une activation excessive des MAP kinases ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent le cancer, des maladies inflammatoires et des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Les troubles cardiovasculaires sont-ils liés aux MAP kinases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une signalisation anormale des MAP kinases peut contribuer à des troubles cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Comment les MAP kinases sont-elles impliquées dans le diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les MAP kinases régulent le métabolisme du glucose, et leur dysfonction peut aggraver le diabète."
}
},
{
"@type": "Question",
"name": "Les maladies neurodégénératives sont-elles liées aux MAP kinases ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies dans la signalisation des MAP kinases peuvent être impliquées dans ces maladies."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une inhibition des MAP kinases ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'inhibition peut entraîner des effets indésirables comme une immunosuppression ou des troubles de la croissance."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux troubles des MAP kinases ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs incluent des prédispositions génétiques, l'exposition à des toxines et le stress."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les risques liés aux MAP kinases ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour les troubles des MAP kinases ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vieillissement peut affecter la signalisation des MAP kinases et augmenter les risques."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles influencer les MAP kinases ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent activer les MAP kinases, contribuant à des maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque pour les troubles des MAP kinases ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut altérer la signalisation des MAP kinases et augmenter le risque de cancer."
}
}
]
}
]
}
Embryonic stem cells (ESCs) preserve the unique ability to differentiate into any somatic cell lineage while maintaining their self-renewal potential, relying on a complex interplay of extracellular s...
To provide more precise treatment options for pancreatic adenocarcinoma (PAAD) patients and improve their prognosis,we established a novel anoikis-related long non-coding RNA signature (ARLSig) to pre...
We downloaded information on PAAD from The Cancer Genome Atlas (TCGA) database, and screened long non-coding RNA (lncRNA) linked with anoikis, and prognostic signatures with these lncRNAs. After that,...
We screened 7 lncRNAs to construct a novel ARLSig and utilized it to predict the efficacy of immunotherapy and the prognosis of PAAD patients....
ARLSig can identify patients who will benefit from immunotherapy and improve the prediction of PAAD patient prognosis....
DNA-damaging agents, including radiation and platinum-based chemotherapy, are indispensable treatments for non-small cell lung cancer (NSCLC) patients. However, cancer cells tend to be resistant to bo...
Cell counting kit (CCK-8), colony formation and flow cytometry were respectively performed to determine the cell cycle and apoptosis of NSCLC cells treated with γ-ray radiation and cisplatin. The exte...
In cell experiments, PANDAR knockdown can increase the sensitivity of NSCLC cells to radiation and cisplatin. The CCK-8 results showed that cell viability was significantly increased in the overexpres...
Our study showed that PANDAR knockdown promoted sensitivity to radiation and cisplatin in NSCLC by regulating the ATR/CHK1 pathway, thus providing a novel understanding as well as a therapeutic target...
Digital programmable coding metasurfaces (DPCMs) have recently attracted enormous attention and have been broadly applied, owing to their ability to manipulate electromagnetic (EM) wave behaviours and...
Childhood immunization remains one of the most cost-effective public health interventions. Globally, millions of children are not being reached with safe and effective vaccines and Nigeria has the hig...
The effects of locally adapted interventions on vaccination timeliness and completeness were studied amongst Fulani populations across 6 health facilities in 2 districts of Bauchi State, Nigeria....
The intervention group consisted of newborns who received 5-color-coded bracelets representing different immunization contacts, while the control group had no bracelets. Vaccination rates across conta...
In this study, 435 children were studied. Vaccination completeness was higher in the intervention group compared to the control group at all contacts during follow-up. The difference was most noticeab...
This study demonstrated the feasibility of a composite intervention (bracelets and PPM) to increase the completeness and timeliness of childhood immunization and provided preliminary evidence for its ...
We have attempted to explore further the involvement of complement components in the host COVID-19 (Coronavirus disease-19) immune responses by targeted genotyping of COVID-19 adult patients and analy...
Cancer is responsible for more than 10 million deaths every year. Metastasis and drug resistance lead to a poor survival rate and are a major therapeutic challenge. Substantial evidence demonstrates t...
Mutations in RNA binding proteins (RBPs) have been linked to the motor neuron disease amyotrophic lateral sclerosis (ALS). Extensive auto-regulation, cross-regulation, cooperation and competition mech...
Emerging evidence suggests that epigenetic alterations are responsible for the oncogenesis and progression of cancer. However, the role of epigenetic reprogramming in pancreatic cancer is still not cl...
Proton therapy is an external radiotherapy using proton beams with energies between 70 and 230 MeV to treat some type of tumours with outstanding benefits, due to its energy transfer plot. There is a ...